Dellis Athanasios, Papatsoris Athanasios G
University Department of Urology, Sismanoglio General Hospital, Athens, Greece.
Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):175-9. doi: 10.1586/14737167.2014.891444. Epub 2014 Feb 25.
Abiraterone acetate is an oral medication that has recently been granted approval for the treatment of metastatic castration resistant prostate cancer (mCRPC) prior and/or after chemotherapy with docetaxel. In this article we assess the economics of abiraterone acetate in mCRPC. Relevant studies demonstrated that abiraterone acetate had a minimal budget impact on health plans. A relevant advantage was the cost savings due to the lack of chemotherapy-related side effects as well as the ease of administration. The results of cost/benefit comparative studies with other novel agents (i.e. cabazitaxel, enzalutamide, sipuleucel-T) are warranted as well as the close collaboration between urologists and medical oncologists.
醋酸阿比特龙是一种口服药物，最近已被批准用于在多西他赛化疗之前和/或之后治疗转移性去势抵抗性前列腺癌（mCRPC）。在本文中，我们评估了醋酸阿比特龙治疗mCRPC的经济学情况。相关研究表明，醋酸阿比特龙对健康计划的预算影响极小。一个相关优势是由于缺乏化疗相关副作用以及给药方便而节省了成本。与其他新型药物（即卡巴他赛、恩杂鲁胺、 sipuleucel-T）进行成本/效益比较研究的结果以及泌尿科医生和医学肿瘤学家之间的密切合作是有必要的。
